PL2491037T3 - Pochodne chinazolin-4(3H)-onu stosowane jako inhibitory kinazy PI3 - Google Patents

Pochodne chinazolin-4(3H)-onu stosowane jako inhibitory kinazy PI3

Info

Publication number
PL2491037T3
PL2491037T3 PL10771416T PL10771416T PL2491037T3 PL 2491037 T3 PL2491037 T3 PL 2491037T3 PL 10771416 T PL10771416 T PL 10771416T PL 10771416 T PL10771416 T PL 10771416T PL 2491037 T3 PL2491037 T3 PL 2491037T3
Authority
PL
Poland
Prior art keywords
quinazolin
kinase inhibitors
derivatives used
derivatives
kinase
Prior art date
Application number
PL10771416T
Other languages
English (en)
Inventor
John King-Underwood
Kazuhiro Ito
Peter John Murray
George Hardy
Frederick Arthur Brookfield
Christopher John Brown
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2491037(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of PL2491037T3 publication Critical patent/PL2491037T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL10771416T 2009-10-19 2010-10-19 Pochodne chinazolin-4(3H)-onu stosowane jako inhibitory kinazy PI3 PL2491037T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0918249.4A GB0918249D0 (en) 2009-10-19 2009-10-19 Compounds
EP10771416.4A EP2491037B1 (en) 2009-10-19 2010-10-19 Quinazolin-4(3h)-one derivatives used as pi3 kinase inhibitors
PCT/EP2010/065746 WO2011048111A1 (en) 2009-10-19 2010-10-19 Compounds

Publications (1)

Publication Number Publication Date
PL2491037T3 true PL2491037T3 (pl) 2014-09-30

Family

ID=41462531

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10771416T PL2491037T3 (pl) 2009-10-19 2010-10-19 Pochodne chinazolin-4(3H)-onu stosowane jako inhibitory kinazy PI3

Country Status (35)

Country Link
US (4) US8741909B2 (pl)
EP (1) EP2491037B1 (pl)
JP (1) JP5889792B2 (pl)
KR (1) KR101770616B1 (pl)
CN (1) CN102712645B (pl)
AR (1) AR078674A1 (pl)
AU (1) AU2010309832B2 (pl)
BR (1) BR112012009214A2 (pl)
CA (1) CA2777902C (pl)
CL (1) CL2012000981A1 (pl)
CR (1) CR20120264A (pl)
CY (1) CY1116057T1 (pl)
DK (1) DK2491037T3 (pl)
EA (1) EA020330B3 (pl)
EC (1) ECSP12011805A (pl)
ES (1) ES2477270T3 (pl)
GB (1) GB0918249D0 (pl)
HR (1) HRP20140599T1 (pl)
IL (1) IL219248A (pl)
ME (1) ME02064B (pl)
MX (1) MX2012004525A (pl)
MY (1) MY164731A (pl)
NI (2) NI201200061A (pl)
NZ (2) NZ599162A (pl)
PE (1) PE20121390A1 (pl)
PH (1) PH12012500620A1 (pl)
PL (1) PL2491037T3 (pl)
PT (1) PT2491037E (pl)
RS (1) RS53385B (pl)
SI (1) SI2491037T1 (pl)
SM (1) SMT201400086B (pl)
TW (1) TWI478923B (pl)
UA (1) UA108743C2 (pl)
WO (1) WO2011048111A1 (pl)
ZA (1) ZA201203662B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101945869B (zh) 2007-12-19 2014-06-18 癌症研究技术有限公司 吡啶并[2,3-b]吡嗪-8-取代化合物及其用途
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011092469A1 (en) 2010-02-01 2011-08-04 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
DK2790705T3 (en) 2011-12-15 2018-03-12 Novartis Ag Use of inhibitors of the activity or function of PI3K
ES2600705T3 (es) * 2012-03-13 2017-02-10 Respivert Limited Inhibidores de PI3 cinasa cristalinos
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
TW201522341A (zh) * 2013-03-15 2015-06-16 Respivert Ltd 化合物
BR112015030881A2 (pt) 2013-06-14 2017-10-24 Psioxus Theraupeutics Ltd “regime de dosagem e formulações para adenovírus de tipo b”
WO2015051244A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3119397B1 (en) 2014-03-19 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
MA40250A (fr) 2014-07-04 2017-05-10 Lupin Ltd Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CN108516976B (zh) * 2018-04-27 2020-07-03 四川大学华西医院 一种7-脱氮嘌呤衍生物及其四元环超分子结构
CN112566639A (zh) * 2018-09-18 2021-03-26 雀巢产品有限公司 用于骨骼肌调节的src抑制剂化合物、其方法和用途
WO2022017371A1 (zh) * 2020-07-21 2022-01-27 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
RU2221552C2 (ru) 1998-11-13 2004-01-20 Джаго Рисерч Аг Сухой порошок для ингаляции
AU779008C (en) 1999-01-11 2005-06-30 Princeton University High affinity inhibitors for target validation and uses thereof
WO2000053157A1 (en) 1999-03-05 2000-09-14 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
EP1278748B1 (en) 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
JP2005509594A (ja) 2001-07-13 2005-04-14 バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド Ｎａｄシンテターゼ阻害剤およびその使用
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2003301662A1 (en) 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
TW201018661A (en) 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
EP1625165A2 (en) 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
WO2005012221A1 (ja) 2003-08-04 2005-02-10 Ono Pharmaceutical Co., Ltd. ジフェニルエーテル化合物、その製造方法および用途
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
WO2005120511A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
TWI400232B (zh) 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
AU2006214190A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
AU2007347115A1 (en) * 2006-04-04 2008-10-23 The Regents Of The University Of California PI3 kinase antagonists
SI2004654T1 (sl) * 2006-04-04 2013-11-29 The Regents Of The University Of California Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
CA2652886A1 (en) 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity
US8022088B2 (en) 2006-06-29 2011-09-20 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP2081892A4 (en) 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
MX2009012066A (es) * 2007-05-09 2009-11-19 Novartis Ag Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
DK2240451T3 (da) * 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
EP2365810A2 (en) 2008-12-04 2011-09-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
US8658648B2 (en) 2008-12-05 2014-02-25 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety
US20110135655A1 (en) * 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
CA2756347A1 (en) * 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
AU2010281265A1 (en) 2009-08-05 2012-03-22 Versitech Limited Antiviral compounds and methods of making and using thereof
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
PL2621494T3 (pl) 2010-09-30 2019-04-30 Chiesi Farm Spa Zastosowanie stearynianu magnezu w preparatach w postaci suchego proszku do inhalacji
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ES2600705T3 (es) 2012-03-13 2017-02-10 Respivert Limited Inhibidores de PI3 cinasa cristalinos

Also Published As

Publication number Publication date
CA2777902C (en) 2018-03-06
US8741909B2 (en) 2014-06-03
CY1116057T1 (el) 2017-02-08
RS53385B (sr) 2014-10-31
TW201124418A (en) 2011-07-16
WO2011048111A1 (en) 2011-04-28
HRP20140599T1 (hr) 2014-09-12
EA020330B1 (ru) 2014-10-30
PE20121390A1 (es) 2012-10-15
EA201270575A1 (ru) 2012-09-28
US9321773B2 (en) 2016-04-26
ME02064B (me) 2015-05-20
ZA201203662B (en) 2013-10-30
MY164731A (en) 2018-01-30
SI2491037T1 (sl) 2014-08-29
CN102712645A (zh) 2012-10-03
SMT201400086B (it) 2014-09-08
US20120208799A1 (en) 2012-08-16
CA2777902A1 (en) 2011-04-28
IL219248A0 (en) 2012-06-28
US20140249164A1 (en) 2014-09-04
NI201300035A (es) 2013-06-04
DK2491037T3 (da) 2014-07-21
IL219248A (en) 2015-02-26
EP2491037B1 (en) 2014-04-30
CN102712645B (zh) 2015-10-21
AU2010309832B2 (en) 2014-01-30
NI201200061A (es) 2013-05-15
US9834560B2 (en) 2017-12-05
EP2491037A1 (en) 2012-08-29
NZ609147A (en) 2014-03-28
CL2012000981A1 (es) 2012-08-31
JP2013508334A (ja) 2013-03-07
EA020330B3 (ru) 2015-07-30
NZ599162A (en) 2013-08-30
AU2010309832A1 (en) 2012-04-19
KR20120114225A (ko) 2012-10-16
AR078674A1 (es) 2011-11-23
UA108743C2 (uk) 2015-06-10
MX2012004525A (es) 2012-05-29
PT2491037E (pt) 2014-07-11
GB0918249D0 (en) 2009-12-02
KR101770616B1 (ko) 2017-08-23
ECSP12011805A (es) 2012-06-29
JP5889792B2 (ja) 2016-03-22
HK1173728A1 (en) 2013-05-24
TWI478923B (zh) 2015-04-01
ES2477270T3 (es) 2014-07-16
BR112012009214A2 (pt) 2016-08-16
US20180118754A1 (en) 2018-05-03
US20160264583A1 (en) 2016-09-15
CR20120264A (es) 2013-01-25
PH12012500620A1 (en) 2015-03-20

Similar Documents

Publication Publication Date Title
PT2491037E (pt) Derivados de quinazolin-4(3h)-ona utilizados como inibidores de pi3-cinases
IL225212A0 (en) History of quinazoline–4 (h3)–ones used as pi3 kinase inhibitors
EP2167092A4 (en) QUINAZOLINE DERIVATIVES AS INHIBITORS OF PI3 KINASE
IL220212A0 (en) Aminopyrimidine kinase inhibitors
EP2211615A4 (en) PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
EP2217590A4 (en) Pyridopyrimidine derivatives as PI3-kinase inhibitors
IL202018A0 (en) Quinoline derivatives as pi3 kinase inhibitors
MX315904B (es) Inhibidores de fosfoinosituro-3 cinasa.
IL218555A0 (en) Pi3 kinase inhibitors and uses thereof
ZA201100344B (en) Pyrimidine derivatives as kinase inhibitors
IL218617A (en) Derivatives of pyridinylimidazolone for inhibition of 3pi kinases
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
EP2173354A4 (en) CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
PL2419427T3 (pl) Dwupierścieniowe pochodne heterocykliczne związków jako kinazy tyrozynowe FGFR do terapeutycznego stosowania
ZA201204246B (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
SI2624696T1 (sl) Benzimidazolni derivati kot inhibitorji pi3-kinaze
IL216411A0 (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors
PT2231642E (pt) Pirimidinas como inibidores de quinase
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
IL219872A0 (en) Quinazoline derivatives
GB0907120D0 (en) Inhibitors of IKK-ß serine-threonine protein kinase
GB0914726D0 (en) Kinase inhibitors